Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford academics partner with SBI Pharmaceuticals to improve cardiac surgery

Clinical Trials Innovation Research

Researchers from the University of Oxford are collaborating with the Japanese pharmaceutical company, SBI Pharmaceuticals, to minimise deterioration of heart function outcomes after cardiac surgery.

© Sergey Nivens - Shutterstock

The Trial of δ--Aminolevulinic Acid to Enhance Myocardial Protection (TALEN) will take place across the John Radcliffe Hospital, Oxford and the Queen Elizabeth Hospital, Birmingham.

During coronary artery bypass surgery or aortic valve replacement, there is a period of time where the heart is without a blood supply, leading to long term damage in some instances. While surgical protocols are in place to limit this damage, TALEN seeks to improve on these established techniques by steeling the heart against injury, prior to surgery. This is the first UK-based clinical trial of its kind using proprietary compound δ--Aminolevulinic Acid (ALA) that SBI Pharmaceuticals has financed.

Read more (Radcliffe Department of Medicine website)

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

Tinnitus seems linked with sleep – understanding how could bring us closer to finding a cure

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.